Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV000469642 | SCV000552365 | likely benign | Tuberous sclerosis 1 | 2023-10-06 | criteria provided, single submitter | clinical testing | |
| Ambry Genetics | RCV002418418 | SCV002720406 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-04-24 | criteria provided, single submitter | clinical testing | The p.D675N variant (also known as c.2023G>A), located in coding exon 14 of the TSC1 gene, results from a G to A substitution at nucleotide position 2023. The aspartic acid at codon 675 is replaced by asparagine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
| All of Us Research Program, |
RCV004001909 | SCV004842735 | uncertain significance | Tuberous sclerosis syndrome | 2023-12-18 | criteria provided, single submitter | clinical testing | This missense variant replaces aspartic acid with asparagine at codon 675 of the TSC1 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with TSC1-related disorders in the literature. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |